In Celexir’s body-recomposition toolkit, Adipotide is positioned strictly as an investigational fat-loss adjunct—used in advanced programs where clinicians are evaluating targeted reduction of stubborn and visceral fat while preserving lean tissue. Catalog guidance frames it for experimental use with full documentation and controlled protocols, not for routine weight-management monotherapy.
How it works: Adipotide is a dual-domain peptide that homes to the vasculature of white adipose tissue and then induces apoptosis in those blood vessels, starving nearby fat cells. The targeting motif (e.g., CKGGRAKDC binding prohibitin/ANXA2 on adipose endothelium) is linked to a pro-apoptotic KLAKLAK sequence, yielding selective effects on fat depots with minimal direct impact on muscle.
Evidence snapshot: In obese rhesus macaques, Adipotide produced rapid fat loss and improved insulin resistance; popular summaries reported ~11% body-weight reduction in ~4 weeks, with dose-dependent, reversible renal effectsnoted as the main safety signal. Early first-in-human Phase 1 efforts were initiated (oncology context), but there is no FDA approval and development has been limited; any clinical deployment should be framed as research-oriented with informed consent.
Celexir delivery & specs: supplied as a lyophilized vial with >98% purity, 2–8 °C storage, and restricted-use documentation; cyclical dosing follows advanced protocols individualized to risk and response, alongside lifestyle pillars (nutrition, resistance training, sleep, metabolic control) and objective tracking (waist/VAT by imaging when feasible, A1c/insulin, lipids, CRP, fitness).